Retatrutide

Descripción

Retatrutide (LY3437943) is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This innovative triple mechanism delivers superior weight loss, increased energy expenditure, and enhanced hepatic fat oxidation compared to dual agonists. In the Phase 2 trial, it achieved a mean weight reduction of 24.2% at 48 weeks; the Phase 3 TRIUMPH-4 trial showed approximately 28–29% average weight loss at 68 weeks, along with significant knee pain improvement. It also offers strong benefits in liver fat reduction, HbA1c lowering, and cardiovascular risk markers, with primarily gastrointestinal side effects typical of incretin therapies. Retatrutide represents the next generation of highly effective metabolic treatments. This content is for research purposes only and is provided solely for reference. It must not be interpreted as health, clinical, or legal advice or guidance.